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Summary
Background: In order to prevent stroke in atrial ﬁbrillation (AF) lower international normalized
ratios (INR) (1.6—2.6) were recommended for elderly Japanese patients, but only one clinical
study supported this recommendation.
Methods and results: The J-RHYTHM Registry is a large, contemporary, prospective observa-
tional investigation, with a 2-year follow-up, of patients with AF. Over 6000 AF patients of
all types under clinical observation at approximately 150 sites in 10 geographical regions that
together cover the whole of Japan will be enrolled in numbers proportional to the popula-
tion densities of those areas. The primary endpoints of the study will be symptomatic stroke
including transient ischemic attack, systemic thromboembolism, and major bleeding including
intracranial hemorrhage requiring hospitalization. At each visit, the accumulated demographic
data and INR will be examined to determine the appropriate INR for Japanese AF patients.
Conclusions: The study will offer a contemporary overview of the anticoagulation status
throughout Japan, and will follo
2 years, to obtain important inf
(UMIN Clinical Trials Registry UM
© 2011 Japanese College of Car
∗ Corresponding author at: Nippon Medical School Tama-Nagayama Hos
Tokyo 206-8512, Japan. Tel.: +81 42 371 2111; fax: +81 42 371 2100.
E-mail address: atarashi@nms.ac.jp (H. Atarashi).
0914-5087/$ — see front matter © 2011 Japanese College of Cardiology.
doi:10.1016/j.jjcc.2010.09.002w more than 6000 patients spread throughout the country for
ormation, including the optimal INR for Japanese AF patients
IN000001569).
diology. Published by Elsevier Ltd. All rights reserved.
pital, Division of Cardiology, 1-7-1 Nagayama, Tama-city,
Published by Elsevier Ltd. All rights reserved.
9I
A
t
l
[
p
p
b
o
t
[
T
m
p
w
h
a
l
l
i
b
A
t
A
O
R
O
T
m
o
a
J
p
t
m
m
I
v
d
[
p
S
P
R
e
w
h
w
c
t
o
r
S
T
i
p
i
l
e
h
a
f
t
t
m
h
a
p
f
p
w
J
i
u
l
s
n
s
d
e
d
p
p
t
t
d
e
l
i
1
n
H
(
H
I
T
a
C
A
O
4
S
(
o
t6
ntroduction
lthough anithrombotic therapy with vitamin K antagonists
o prevent thromboembolism in patients with atrial ﬁbril-
ation (AF) has been recommended in clinical guidelines
1,2], the restrained use of warfarin is still a part of general
ractice. At present, it is widely accepted that maximum
rotection against ischemic stroke in an AF patient is proba-
ly achieved in an international normalized ratio (INR) range
f 2.0—3.0. However, a previous clinical report stated that
he optimal INR was 1.6—2.6 in elderly Japanese AF patients
3] at the time of their secondary prevention of stroke.
here are racial differences in the safety of warfarin, which
ay increase the risk of intracranial hemorrhage among AF
atients in Asia [4—7]. According to Shen et al. [4], non-
hite patients, especially Asians, with AF are at risk of such
emorrhages due to warfarin use. We will therefore conduct
n investigation of the appropriate intensity of anticoagu-
ation in Japanese AF patients. The J-RHYTHM Registry is a
arge, contemporary, prospective AF registry for investigat-
ng not only the present status of anticoagulation therapy,
ut also the optimal anticoagulation therapy for Japanese
F patients. The present study is the ﬁrst trial that inves-
igates appropriate INR for primary prevention in Japanese
F patients.
bjectives and study design of the J-RHYTHM
egistry
bjectives
he J-RHYTHM Registry is a prospective observational accu-
ulation of data employed in the investigation of the
ptimal intensity of anticoagulation in Japanese AF patients
nd of the present status of anticoagulation treatment in
apan.
The purposes of this study are, ﬁrstly, to investigate the
resent status of anticoagulation treatment and to explore
he optimal INR for Japanese AF patients; secondly, to deter-
ine the appropriate indices for ischemic stroke and for
ajor bleeding; and, thirdly, to explore the variations in
NR control among the 10 regions and to observe how these
ariations affect the primary endpoints. A further goal is to
etermine the appropriate time-in-therapeutic range (TTR)
8] to achieve beneﬁt from warfarin therapy in this series of
atients.
tudy population
atients will be eligible for enrollment into the J-RHYTHM
egistry if they are aged ≥20 years and have had at least one
pisode of AF on a standard 12-lead electrocardiogram. We
ill enroll a consecutive series of AF patients of all types who
ave maintained a sinus rhythm for more than 1 year, and
ill keep them under clinical observation in the outpatient
linic at each institution. In-patients will be excluded from
he study. The study protocol must be approved by each
f the participating institutions, and all participants will be
equired to give written informed consent.
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tudy design and patient enrollment
he J-RHYTHM Registry is a prospective, observational reg-
stry with a 2-year follow-up period. During this period all
articipants must revisit their cardiologists at the usual
ntervals, and patients taking warfarin will be revisited at
east once every 2 months for INR to be determined. At
ach visit to the cardiologist, peripheral blood pressure,
eart rate, and changes in prescription will be recorded,
nd the daily warfarin dose and INR value will be noted
or all patients taking warfarin. The primary endpoints of
his observational study are symptomatic stroke including
ransient ischemic attack (TIA), systemic thromboembolism,
ajor bleeding including intracranial hemorrhage requiring
ospitalization, and all causes of death. Any patient in whom
primary endpoint is encountered will be evaluated by com-
uted tomography (CT) or magnetic resonance imaging (MRI)
or precise diagnosis and require an INR value on the closest
ossible day to their revisit day to their cardiologist.
We estimated that a total of at least 6000 patients
ould be needed for evaluation of the appropriate INR for
apanese patients, and expected a risk level of 2.5% per year
n Japanese AF patients [9,10], or of 5% with a 2-year follow-
p period. For the analysis of such epidemiological data, at
east 200 events are required. Therefore, we initially con-
idered that the data of more than 4000 patients would be
eeded for this project, and therefore that 6000 patients
hould be examined to obtain sufﬁcient data (allowing for
ropouts, deaths, etc.) for the Registry.
Efforts will be made to recruit consecutive patients at
ach site to avoid patient selection bias, and to avoid
ifferences of treatment skills between institutions, and
hysicians at each site will recruit a maximum of 100
atients (the average target number being 60). We expect
hat a total of 150 sites across Japan will be needed for
he enrollment process. Also, to avoid uneven regional
istribution of the study population, the number of patient-
nrollments will reﬂect the population density of the
ocality. Therefore, patient registration will be carried out
n proportion to the population density from each of the
0 Japanese geographical divisions (Fig. 1). The target
umbers for enrollment in each area will be as follows:
okkaido area, 300 patients; Tohoku area, 500 patients
including Aomori, Akita, Yamagata, Iwate, Fukushima);
okuetsu area, 300 patients (including Niigata, Toyama,
shikawa, Fukui); North Kanto area, 650 patients (including
ochigi, Ibaragi, Saitama, Gunma, Yamanashi); South Kanto
rea, 1200 patients (including Chiba, Tokyo, Kanagawa);
hubu area, 800 patients (including Shizuoka, Nagano,
ichi, Mie, Gifu); Kansai area, 900 patients (including
saka, Shiga, Hyogo, Nara, Wakayama); Chugoku area,
00 patients (Okayama, Hiroshima, Yamaguchi, Tottori,
himane); Shikoku area, 250 patients; and Kyushu area
including Okinawa), 700 patients.
All participants, including the Local Executive Committee
f the J-RHYTHM Registry (members of advisory board of
he Japanese Society of Electrocardiology), are cardiologists
elected by the Steering Committee (see Appendix A). The
uration of enrollment in each practice setting is estimated
o be 3 months from the ﬁrst to the last patient enrolled.
he enrollment will occur all over Japan between January
010 and July 2010.
J-RHYTHM Registry study design 97
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Evaluations
Subjects will be evaluated at baseline for demographic data
and status of medical treatment including the anticoag-
ulation regimen presented in Table 1. When warfarin is
administered, the value of INR is needed. The risk of stroke
will be evaluated with the CHADS2 score [11], and demo-
graphic data will be obtained from all outpatients’ clinical
charts. The presence of diabetes will be diagnosed using
glycated hemoglobin A1c 6.5% as a standard [12], or will be
assumed if a patient is taking medication for the treatment
of diabetes. Hypertension will be diagnosed if the periph-
eral blood pressure is >140/90mmHg [13], if the patient is
taking medication for hypertension, or if the patient has a
history of hypertension.
Clinical parameters including heart rate, peripheral
blood pressure, medication for an underlying disease, and
treatment with warfarin and antiplatelet drugs will be evalu-
ated at baseline. At each revisit during the 2-year follow-up,
investigation of the daily doses of warfarin, the value of
INR, and the prescription of antiplatelet drugs are manda-
tory. In patients taking warfarin, the INR will be measured at
D
T
w
ithe target numbers for enrollment in each area.
east once every 2 months over the 2-year follow-up period.
ollected data are sent automatically by e-mail using a for-
atted USB memory stick to the data center (Medisket Co.,
okyo, Japan) for storage in the Electronic Data Capture Sys-
em after completion of the registry. All AF patients will
eturn to, and be followed up at, their outpatient clinic at
ach institution. During the follow-up period, if any event
ccurs, it is mandatory that the ﬁnal clinical data at the
losest time to the event be sent to the data center.
After completion of a 2-year follow-up, the event rate
f the primary endpoints will be calculated as a function of
HADS2, and, to establish a new scoring system for bleeding,
e will calculate the factors in the clinical background. The
iagnosis of the type of stroke will be performed by two
troke specialists by means of CT or MRI taken at the time
hen the event occurred.ata analysis
o establish a Japanese patient’s speciﬁc optimal INR range,
e will evaluate the frequency of symptomatic stroke
ncluding TIA and major bleeding. The target intensity of
98
Table 1 Evaluations that will be performed at baseline,
and at the 2-year follow-up visit.
Evaluations at baseline Evaluations during
2-year follow-up
Demographic
information (age, sex)
Physical examination
Medical history Peripheral blood
pressure
Risk factors for
thromboembolism
(CHADS2 score)
Heart rate
Physical examination Laboratory
information
Peripheral blood
pressure
International
normalized ratio
Heart rate Medications
Laboratory information Warfarin
Hemoglobin Antiplatelets
Platelet count
Serum creatinine
International
normalized ratio
Medications
Warfarin
Antiplatelets
Antihypertensives
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RMedication for
diabetes mellitus
Antiarrhythmics
nticoagulation will minimize the occurrence of ischemic
troke and hemorrhagic complications. To determine the
ptimal range of INR, we will use the odds ratio for stroke
nd intracranial bleeding in relation to the intensity of
nticoagulation [14]. To calculate the percentage of major
leeding by the new scoring system for bleeding, we will
se an exponential survival model [15]. The TTR will be
alculated by the method ﬁrst described by Rosendaal et
l. [8], which uses linear interpolation of INR values in
ach patient under warfarin treatment to calculate the per-
entage of days when the INR is in the therapeutic range
2.0—3.0). Data collected at the Registry are expressed
s mean± SD, and baseline differences between any two
roups are evaluated with 2 tests for categorical variables,
nd with Student’s t-test for continuous variables. To com-
are the average value of the CHADS2 score in each group
nd the differences in the CHADS2 scores among the types
f AF, the Wilcoxon rank-sum test and the Kruskal—Wallis
est, respectively, are used. For all the analyses, a two-sided
robability value <0.05 is considered statistically signiﬁcant.
nalysis will be performed with SAS version 9.1 statistical
oftware.
xpected implicationshe J-RHYTHM Registry is the ﬁrst large-scale investigation
o clarify the frequency of warfarin use at cardiology clin-
cs in medium-sized to large hospitals and determine the
ppropriate intensity of warfarin therapy in Japanese AFH. Atarashi et al.
atients. For the prevention of stroke in AF patients, guide-
ines of western countries recommended INR 2.0—3.0, but
heir validity has never been conﬁrmed in Japanese patients.
here are some reports that even if INR intensity is within
his range, and thus appears to be adequate, the risk of
ntracranial hemorrhage among AF patients in Asia may still
e increased [4—7]. In Japanese AF patients, only one clin-
cal study suggested that INR≥ 2.6 may increase bleeding
omplications and that 1.6≥ INR may increase the risk of
evere stroke [3]. Therefore, we will establish the J-RHYTHM
egistry to conﬁrm the appropriate INR range for Japanese
F patients. Simultaneously, this study will accumulate the
argest database of the status both of AF patients and of con-
emporary anticoagulation in Japan. All of this information
ould make possible further improvement of AF manage-
ent, especially stroke prevention, not only for Japanese
ardiologists but also for cardiologists in other Asian coun-
ries.
ole of the funding source
he J-RHYTHM Registry is a project planned by the Japanese
ociety of Electrocardiology and partially supported by the
apanese Heart Foundation. The sponsor had no role in the
tudy design or in the conduct of the study, the collection of
he data, its analysis or its interpretation, or in the prepa-
ation of the present manuscript. The corresponding author
ad full access to all the data and takes full responsibility
or the integrity of the data in this study, as well as for the
ecision to submit this manuscript for publication.
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ppendix A.
he following persons participated in this trial: The Steer-
ng Committee: Inoue H, Okumura K, Atarashi H, Yamashita
; Local Executive Committee: Sakurai M, Kawamura Y
Hokkaido); Okumura K, Kubota I (Tohoku); Kaneko Y, Matu-
oto K (North Kanto); Ogawa S, Atarashi H, Yamashita
(South Kanto); Inoue H, Aizawa Y (Hokuetsu); Kodama
, Watanabe E (Chubu); Koretsune Y, Okuyama Y (Kan-
ai); Shimizu A, Igawa O (Chugoku); Bando S, Fukatani M
Shikoku); Saikawa T, Chishaki A (Kyushu); Statistical Analy-
is: Origasa H.
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